ReviewJournal of personalized medicine2024
Diagnosis, Prevention, and Management of Fetal Growth Restriction (FGR).
Review in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Women's perspectives on fetal movement monitoring in high and low stillbirth settings: a mixed-methods study.BMC pregnancy and childbirth · 2026Article
- Maternal serum sex hormone-binding globulin and androgen levels in fetuses with intrauterine growth restriction: a prospective case-control study.Archives of gynecology and obstetrics · 2026Article
- Association of obstetrics and foetal ultrasound parameters with maternal serum Lamin A: A teaching institution-based cross-sectional study.Journal of family medicine and primary care · 2026Article
- Diameter of the fetal pancreas and abdomen-to-pancreas-ratio: novel ultrasound parameters in fetal growth restriction.Archives of gynecology and obstetrics · 2026Article
- Promoter landscape of maternal plasma DNA reveals predictive signatures of fetal growth restriction.Human genomics · 2026Article
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
- Maternal migraine, vascular comorbidities, and prematurity: exploring overlooked associations in pregnancy.Frontiers in global women's health · 2026Article
- Article
- A pediatric patient with Warsaw breakage syndrome presenting with epilepsy: a case report and literature review.Frontiers in neuroscience · 2026Article
- From Preconception to Postnatal: Parental Risk Factors for Fetal-Infant Growth Faltering in LMICs-a Scoping Review (2020-2025).Journal of multidisciplinary healthcare · 2026Review
- Real-time quality feedback on Doppler data for community midwives using edge-AI.Machine learning. Health · 2025Article
- Uli-epic: profiling RNA modifications from ultra-low input samples.Genome biology · 2025Article
- Clinical Presentation and Management of Acute Exacerbation of Asthma During Pregnancy at a Tertiary Care Hospital.Cureus · 2025Article
- Cardiac biomarkers in term newborns with common pathological conditions during the first 24 hours postpartum.Biochemia medica · 2025Article
- Pregnancy Under Pressure: Oxidative Stress as a Common Thread in Maternal Disorders.Life (Basel, Switzerland) · 2025Review
- Survivin Expression in Placentas with Intrauterine Growth Restriction.Biomedicines · 2025Article
- Review
- From infection to infertility: a review of the role of human papillomavirus-induced oxidative stress on reproductive health and infertility.European journal of medical research · 2025Review
- Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology.Frontiers in immunology · 2025Article
- Psychological Experiences of Pregnant Women with Fetal Growth Restriction in China: A Qualitative Study.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal growth restriction (FGR), or intrauterine growth restriction (IUGR), is still the second most common cause of perinatal mortality. The factors that contribute to fetal growth restriction can be categorized into three distinct groups: placental, fetal, and maternal. The prenatal application of various diagnostic methods can, in many cases, detect the deterioration of the fetal condition in time because the nature of the above disorder is thoroughly investigated by applying a combination of biophysical and biochemical methods, which determine the state of the embryo-placenta unit and assess the possible increased risk of perinatal failure outcome and potential for many later health problems. When considering the potential for therapeutic intervention, the key question is whether it can be utilized during pregnancy. Currently, there are no known treatment interventions that effectively enhance placental function and promote fetal weight development. Nevertheless, in cases with fetuses diagnosed with fetal growth restriction, immediate termination of pregnancy may have advantages not only in terms of minimizing perinatal mortality but primarily in terms of reducing long-term morbidity during childhood and maturity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.